TIPRL and uterine cancer: Similar mechanisms have been reported in other cancers: in uterine cancer, PPP2R1A mutations exert a dominant-negative effect by binding to TIPRL1, inhibiting PP2A activity, and activating oncogenic pathways such as AKT to promote malignant growth (39).